A vs BRKR vs QGEN Stock Comparison

Agilent Technologies, Bruker and Qiagen Prices as of Nov 13, 2026 Peers: Industry group
A Agilent Technologies, Inc.
$173.91 -0.1% 1M +18.4% 1Y
Market cap
$49.04B
P/E
34.1x
Revenue (TTM)
$7.37B
Div. yield
0.60%
Life Sciences Tools Healthcare
7 wins
BRKR Bruker Corp
$61.59 +10.8% 1M +47.4% 1Y
Market cap
$9.41B
P/E
–
Revenue (TTM)
$3.51B
Div. yield
0.32%
Life Sciences Tools Healthcare
1 win
QGEN Qiagen N.V.
$49.90 +9.6% 1M +6.2% 1Y
Market cap
$10.82B
P/E
28.2x
Revenue (TTM)
$2.12B
Div. yield
5.29%
Life Sciences Tools Healthcare
4 wins

Head to Head

12 decided of 12

Agilent Technologies leads on 7 of the 12 questions below (Agilent Technologies 7, Qiagen 4, Bruker 1). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionABRKRQGENLeader
Larger companyMarket capitalisation $49.04B $9.41B $10.82B A
Cheaper on earningsLower P/E, profitable companies only 34.1x -56.1x 28.2x QGEN
Cheaper on forward earningsLower price / next fiscal year consensus EPS 26.6x 28.0x 21.2x QGEN
Faster revenue growthRevenue growth, trailing twelve months +8.6% +2.2% +2.2% A
More profitableNet margin, trailing twelve months 19.5% -4.8% 18.2% A
Better return on capitalReturn on invested capital 13.1% -1.7% 7.4% A
Less leveragedLower net debt / EBITDA 1.1x 10.0x 1.2x A
Higher dividend yieldTrailing dividend yield 0.60% 0.32% 5.29% QGEN
Better 1-year returnPrice return, last 12 months +18.4% +47.4% +6.2% BRKR
Better 5-year returnAnnualised price return, 5 years +1.6%/yr -5.7%/yr -3.6%/yr A
Less volatileAnnualised volatility, 1 year 32.8% 62.4% 35.2% A
Higher overall scoreMean of the five percentile scores vs peers 61/100 48/100 69/100 QGEN

Percentile Scorecard

ABRKRQGEN

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisABRKRQGEN
Valuation 60 #98 of 243 69 #77 of 243 74 #63 of 243
Growth 37 #144 of 228 18 #187 of 228 25 #171 of 228
Profitability 93 #17 of 222 63 #82 of 222 93 #16 of 222
Financial Health 53 #117 of 248 19 #200 of 248 60 #100 of 248
Shareholder Returns 64 #57 of 158 69 #50 of 158 94 #11 of 158
Overall 61 48 69
  • A ranked among 252 companies in Medical Devices and Diagnostics
  • BRKR ranked among 252 companies in Medical Devices and Diagnostics
  • QGEN ranked among 252 companies in Medical Devices and Diagnostics

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodABRKRQGENSPY
1 month -0.1%+10.8%+9.6% -2.0%
3 months +17.1%+6.7%+16.2% -2.8%
6 months +55.7%+43.6%+51.3% +2.0%
Year to date +27.8%+30.7%+5.4% +10.6%
1 year +18.4%+47.4%+6.2% +12.2%
3 years +55.8%-0.1%+13.0% +68.1%
3 years, per year +15.9%0.0%+4.2% +18.9%
5 years +8.1%-25.4%-16.9% +61.4%
5 years, per year +1.6%-5.7%-3.6% +10.1%
10 years +275.0%+169.3%+56.5% +248.5%
10 years, per year +14.1%+10.4%+4.6% +13.3%

Risk

MeasureABRKRQGENSPY
Volatility, 1Y 32.8%62.4%35.2% 13.6%
Downside volatility, 1Y 28.1%59.9%29.7% 13.9%
Beta vs S&P 500, 1Y 0.911.750.38 1.00
Return / volatility, 1Y 0.560.760.18 0.90
Max drawdown, 5Y -39.6%-68.9%-48.2% -25.4%
From 52-week high -4.2%-7.4%-10.3% -3.2%
52-week high $181.54$66.54$55.66 $779.14
52-week low $110.24$32.76$32.63 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleABRKRQGEN
P/E now vs peer median 34.1xmedian 26.5x -56.1xmedian 26.5x 28.2xmedian 26.5x
P/S now vs peer median 6.7xmedian 2.7x 2.7xmedian 2.7x 5.1xmedian 2.7x
EV/EBITDA now vs peer median 26.8xmedian 18.4x 69.3xmedian 18.4x 17.7xmedian 18.4x
P/FCF now vs peer median 38.7xmedian 25.4x 38.4xmedian 25.4x 11.2xmedian 25.4x
P/B now vs peer median 6.7xmedian 2.5x 4.1xmedian 2.5x 3.1xmedian 2.5x
PEG now vs peer median 3.46median 0.98 1.57median 0.98 11.74median 0.98

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsABRKRQGEN
Revenue $7.37B $3.51B $2.12B
Gross profit $3.97B $1.67B $1.33B
Operating income $1.64B -$69.80M $448.74M
Net income $1.44B -$115.70M $384.93M
Free cash flow $1.27B $244.70M $964.47M
R&D $485.00M $387.20M $199.87M
EPS (diluted) $5.09 $-1.10 $1.76
Cash & equivalents $1.76B $119.70M $805.13M
Total debt $3.95B $1.71B $1.64B
Shares (diluted) 283.00M 152.50M 218.88M
Enterprise value $41.92B $8.71B $7.46B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricABRKRQGEN
P/E 34.1x -56.1x 28.2x
P/FCF 38.7x 38.4x 11.2x
P/Operating cash flow 30.5x 27.5x 17.0x
P/S 6.7x 2.7x 5.1x
P/B 6.7x 4.1x 3.1x
P/Tangible book 7.6x 4.2x 3.4x
EV/EBITDA 26.8x 69.3x 17.7x
EV/EBIT 31.3x -157.6x 25.9x
EV/Revenue 6.9x 3.1x 5.5x
EV/FCF 40.4x 45.0x 12.1x
EV/Operating cash flow 31.8x 32.2x 18.3x
PEG (3Y EPS CAGR) 3.46 1.57 11.74

Growth

14 metrics
MetricABRKRQGEN
Revenue growth (1Y) 8.6% 2.2% 2.2%
Revenue CAGR (3Y) 1.8% 7.6% 2.7%
Gross profit growth (1Y) 11.2% 3.2% 1.7%
Gross profit CAGR (3Y) 3.7% 4.9% 2.5%
Operating income growth (1Y) 13.5% -209.1% -7.6%
Operating income CAGR (3Y) 5.1% -29.1% 3.6%
Net income growth (1Y) 18.0% -390.3% -2.8%
Net income CAGR (3Y) 8.3% -33.1% 5.0%
EPS growth (1Y) 18.9% -602.7% -7.3%
EPS CAGR (3Y) 9.8% -35.8% 2.4%
Operating cash flow growth (1Y) 7.6% 262.5% -3.4%
Operating cash flow CAGR (3Y) -1.9% 2.6% 13.7%
Free cash flow growth (1Y) 16.5% 2,408% 1.1%
Free cash flow CAGR (3Y) -3.7% 5.9% 13.5%

Profitability

14 metrics
MetricABRKRQGEN
Gross margin 53.8% 47.7% 62.8%
EBITDA margin 25.9% 4.5% 31.0%
Operating margin 22.2% -2.0% 21.2%
Pretax margin 22.5% -2.0% 21.7%
Net margin 19.5% -4.8% 18.2%
FCF margin 17.2% 7.0% 45.6%
Operating cash flow margin 21.8% 9.7% 30.0%
Return on equity 19.9% -4.9% 11.3%
Return on assets 10.7% -2.0% 6.5%
Return on invested capital 13.1% -1.7% 7.4%
Return on capital employed 14.6% -1.5% 8.5%
Asset turnover 0.5x 0.6x 0.4x
Cash conversion (OCF / net income) 1.1x -3.0x 1.6x
Stock comp / revenue 1.8% – 2.0%

Financial Health

11 metrics
MetricABRKRQGEN
Debt / assets 28.3% 29.4% 27.6%
Debt / equity 0.5x 0.7x 0.5x
Net debt / EBITDA 1.1x 10.0x 1.2x
Debt / FCF 3.1x 7.0x 1.7x
Liabilities / assets 47.3% 60.4% 41.5%
Equity / assets 52.7% 39.6% 58.5%
Interest coverage 15.5x -1.2x 10.8x
Current ratio 2.1x 1.8x 2.6x
Quick ratio 1.4x 0.7x 1.9x
Cash ratio 0.8x 0.1x 1.3x
Altman Z-score 5.77 – 4.14

Shareholder Returns

7 metrics
MetricABRKRQGEN
Dividend yield 0.6% 0.3% 5.3%
Net buyback yield 0.6% – 0.6%
Shareholder yield 1.2% 0.3% 5.9%
Payout ratio (earnings) 19.9% -26.2% –
Payout ratio (FCF) 22.6% 12.4% –
Dividend growth (1Y) 2.1% 32.3% –
Dividend CAGR (3Y) 3.1% 0.9% –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusABRKRQGEN
Forward P/E 26.6xFY2026 28.0xFY2026 21.2xFY2026
EPS, next fiscal year $6.54FY2026 $2.20FY2026 $2.35FY2026
EPS growth, next FY +17.0%FY2026 +20.2%FY2026 -1.3%FY2026
EPS growth, the year after +0.2% +5.5% +17.9%
Revenue, next fiscal year $7.87BFY2026 $3.76BFY2026 $2.25BFY2026
Revenue growth, next FY +15.3%FY2026 +9.4%FY2026 +7.8%FY2026
Revenue growth, the year after -5.6% +2.7% -2.8%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersABRKRQGEN
Held by institutions 92.6% 93.1% 67.3%
Institutions holding 1,126 418 338
Change in shares held, QoQ +3.2% +3.6% +16.5%
Institutions buying 601 249 216
Institutions selling 351 122 86
Buyers to sellers 1.71 2.04 2.51

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

ABRKRQGEN
A 1.00 0.62 0.37
BRKR 0.62 1.00 0.38
QGEN 0.37 0.38 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, A, BRKR and QGEN?

Agilent Technologies (A) is the largest by market capitalisation: Agilent Technologies (A) $49.04B, Bruker (BRKR) $9.41B, Qiagen (QGEN) $10.82B.

Which stock is cheaper, A, BRKR and QGEN?

Qiagen (QGEN) trades on the lowest price-to-earnings ratio (Agilent Technologies (A) 34.1x, Bruker (BRKR) -56.1x, Qiagen (QGEN) 28.2x). On next year's consensus earnings, Qiagen (QGEN) is cheapest (Agilent Technologies (A) 26.6x, Bruker (BRKR) 28.0x, Qiagen (QGEN) 21.2x). A lower multiple can reflect slower expected growth, so read it next to the growth figures.

Which company is growing faster?

Agilent Technologies (A) grew revenue fastest over the trailing twelve months: Agilent Technologies (A) +8.6%, Bruker (BRKR) +2.2%, Qiagen (QGEN) +2.2%.

Which company is more profitable?

Agilent Technologies (A) has the highest net margin (Agilent Technologies (A) 19.5%, Bruker (BRKR) -4.8%, Qiagen (QGEN) 18.2%). On return on invested capital, Agilent Technologies (A) leads (Agilent Technologies (A) 13.1%, Bruker (BRKR) -1.7%, Qiagen (QGEN) 7.4%).

Which stock has performed better?

Over the past year Bruker (BRKR) returned the most: Agilent Technologies (A) +18.4%, Bruker (BRKR) +47.4%, Qiagen (QGEN) +6.2%. Over five years, Agilent Technologies (A) compounded fastest (Agilent Technologies (A) +1.6%/yr, Bruker (BRKR) -5.7%/yr, Qiagen (QGEN) -3.6%/yr). Returns are price only, before dividends.

Which pays a higher dividend?

Qiagen (QGEN) has the highest dividend yield: Agilent Technologies (A) 0.60%, Bruker (BRKR) 0.32%, Qiagen (QGEN) 5.29%.

Which stock is riskier?

By one-year price volatility, Agilent Technologies (A) has been the steadiest (Agilent Technologies (A) 32.8%, Bruker (BRKR) 62.4%, Qiagen (QGEN) 35.2%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, A, BRKR and QGEN?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Agilent Technologies (A) leads on 7. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.